Tissue Engineering Market By Product Type, By Manufacturers, By End-User And Market Trend Analysis Forecast 2033

The Tissue Engineering by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Tissue Engineering Market:

https://www.thebusinessresearchcompany.com/report/tissue-engineering-global-market-report

According to The Business Research Company’s Tissue Engineering, The tissue engineering market size has grown rapidly in recent years. It will grow from $13.36 billion in 2023 to $15.38 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to advancements in biomaterials, growing aging population, increasing incidence of chronic diseases, regulatory support for regenerative medicine, rising patient demand for organ transplants.

The tissue engineering market size is expected to see rapid growth in the next few years. It will grow to $26.33 billion in 2028 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to precision medicine approaches, increasing focus on immunomodulation, expanding applications in orthopedics, increased funding and investment, rising prevalence of chronic diseases. Major trends in the forecast period include integration of nanotechnology, 3d cell culture techniques, development of organ-on-a-chip technology, artificial intelligence integration,innovative cell sources.

The increase in the prevalence of chronic diseases and trauma emergencies is expected to propel the growth of the tissue engineering market going forward. Chronic diseases refer to clinical conditions that last for 3 months or longer periods and usually can be controlled but not cured, whereas trauma emergencies refer to any physical injury that requires immediate medical attention due to its sudden onset and severity such as traumatic brain injuries. Tissue engineering is widely adopted by healthcare professionals for its various advantage in treating chronic disorders and trauma to avoid end-stage treatment failure including autologous or allograft transplantation, xenotransplantation, and artificial substitutes. For instance, in March 2021, according to the Mary Ann Liebert, Inc. article, a US-based privately held independent publishing company, approximately 2% of the total population in the United States are affected by chronic wounds. Further, in 2020, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency that operates in the prevention and control of disease and injury, around 64,000 occurred in the United States due to traumatic brain injuries and approximately176 deaths every day by TBI. Therefore, the increase in the prevalence of chronic diseases and trauma emergencies is driving the growth of the tissue engineering market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9535&type=smp

The tissue engineering market covered in this report is segmented –

1) By Type: Synthetic Scaffold Material, Biologically Derived Scaffold Material, Other Types

2) By Application: Orthopedics And Musculoskeletal, Neurology, Cardiovascular, Skin And Integumentary, Dental, Other Applications,,,,

3) By End-User: Hospitals And Clinics, Ambulatory Facilities

Technological advancement is the key trend that is gaining popularity in the tissue engineering market. Major companies operating in the market are focused on research and development for product innovations that could give better solutions and strengthen their position in the market. For instance, in March 2021, CELLINK, a US-based company operating in tissue engineering introduced its advanced bioprinter that works on 3D bioprinting technology known as BIO MDX Series. 3D bioprinting technology refers to technology that uses bio-inks and living cells to construct natural 3D tissue structures. BIO MDX Series consists of printheads, nanoliter, and picoliter dispensing channels along with robotic integration that provides precision bioprinting for high-throughput fabrication that can be used in advanced cell-based technologies.

The tissue engineering market report table of contents includes: